Party Secretary Li holds video conference with BioNTech CEO

Qian Tong
Shanghai Party Secretary Li Qiang yesterday held a video conference with Ugur Sahin, chief executive officer and co-founder of Germany pharmaceutical firm BioNTech.
Qian Tong
Party Secretary Li holds video conference with BioNTech CEO

Shanghai Party Secretary Li Qiang in the video conference yesterday.

Shanghai Party Secretary Li Qiang yesterday held a video conference with Ugur Sahin, chief executive officer and co-founder of Germany pharmaceutical firm BioNTech, on cooperation in developing vaccines against the novel coronavirus.

“We hope BioNTech and Fosun Pharma Industrial will strengthen cooperation in developing safe and reliable vaccines against the coronavirus and innovative therapies, and carry out comprehensive cooperation in research and development, and production of biomedicines in Shanghai,” Li said.

He added that Shanghai will continue to deepen reform and opening up under the leadership of President Xi Jinping, push forward the development of the economy and society against the COVID-19 pandemic, and continue to create a first class business environment to provide excellent service for enterprises from home and abroad to develop in Shanghai.

Party Secretary Li holds video conference with BioNTech CEO

Ugur Sahin, chief executive officer and co-founder of Germany pharmaceutical firm BioNTech, in the video conference yesterday.

Sahin introduced details about the R&D and clinical tests of mRNA-based therapies against the coronavirus. “As an international biomedicine company, BioNTech has a deep understanding of the importance of international cooperation on the basis of mutual respect and trust,” he noted.

City leader Zhuge Yujie also joined the video conference.

On March 16, Fosun Pharma Industrial announced a strategic development and commercialization collaboration with BioNTech to advance an mRNA vaccine in China for the prevention of COVID-19 infection.

The two parties will collaborate to conduct clinical trials in China leveraging Fosun Pharma’s extensive clinical development, regulatory and commercial capabilities in the country with the vaccine supplied by BioNTech’s manufacturing facilities in Europe.


Special Reports

Top